Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for constructing breast cancer neoadjuvant chemotherapy effect classification model

A classification model, a technique for breast cancer, used in medical reference, character and pattern recognition, healthcare informatics, etc.

Pending Publication Date: 2019-12-13
广州市雄基生物信息技术有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current markers used to monitor breast cancer are tumor antigen 15-3 and 27-29, but their sensitivity is estimated to be only 60-70%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for constructing breast cancer neoadjuvant chemotherapy effect classification model
  • Method for constructing breast cancer neoadjuvant chemotherapy effect classification model
  • Method for constructing breast cancer neoadjuvant chemotherapy effect classification model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1 Prediction of curative effect of the combination regimen of epirubicin, cyclophosphamide and paclitaxel in neoadjuvant chemotherapy for breast cancer

[0060] Step 1: Sample collection: collect peripheral blood from 26 breast cancer patients before neoadjuvant chemotherapy with epirubicin, cyclophosphamide, and paclitaxel, and evaluate the curative effect after 8 cycles of chemotherapy, according to RECIST1.0 Evaluation criteria, including 18 cases achieved PR effect, 8 cases achieved SD effect, 7 cases reached pCR according to whether pCR standard was met, and 19 cases did not reach pCR (npCR), as shown in Table 1.

[0061] Step 2: Plasma separation: The collected peripheral blood was centrifuged at 4°C and 1600g for 10 minutes, and the supernatant was centrifuged at 4°C and 16000g for 10 minutes for plasma separation. Be careful not to absorb white blood cells.

[0062] Step 3: Plasma cfDNA extraction: Plasma cfDNA was extracted using a plasma free DNA extra...

Embodiment 2

[0074] Example 2 Efficacy Prediction of Neoadjuvant Chemotherapy for Breast Cancer Epirubicin, Cyclophosphamide, Paclitaxel, and Carboplatin

[0075] Step 1: Collect peripheral blood from 8 breast cancer patients before neoadjuvant chemotherapy with epirubicin, cyclophosphamide, paclitaxel, and carboplatin, and evaluate the curative effect after 8 cycles of chemotherapy. Among them, 3 patients achieved pCR There were 5 patients who did not reach pCR (npCR), as shown in Table 1.

[0076] Steps 2-6 are the same as steps 2-6 in Embodiment 1, and the grouping method is only according to the grouping method of pCR and npCR.

[0077] The result is as image 3 As shown, based on the high-throughput detection of plasma cell-free DNA from 8 breast cancer patients who received a combined regimen of epirubicin, cyclophosphamide, paclitaxel, and carboplatin, and analyzed the coverage of TSSs, it was found that the pCR group was significantly different from the npCR group. A total of 555...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for constructing a breast cancer neoadjuvant chemotherapy effect classification model. The method comprises obtaining the plasma cfDNA sequencing data of a patient with a known curative effect and performing TSSs area coverage analysis; determining a coverage difference and then performing cluster analysis to obtain a classification model. The model constructed bythe method of the invention can realize the effect prediction of neoadjuvant chemotherapy for a breast cancer patient, determines the treatment strategy of the breast cancer, and guides the breast cancer neoadjuvant chemotherapy for. The data required by the model of the present invention derives from peripheral blood and belongs to the category of noninvasive detection. The method solves the poorclinical experience, the incapability of solving tumor heterogeneity, the puncture contraindications, and the risk of tumor spread and metastasis caused by the need for invasive puncture sampling ofan existing material for predicting the efficacy of the breast cancer neoadjuvant chemotherapy,.

Description

technical field [0001] The invention relates to a method for constructing a classification model and a kit, in particular to a method for constructing a classification model for the curative effect of neoadjuvant chemotherapy for breast cancer by using the TSSs region in plasma cfDNA. Background technique [0002] Neoadjuvant chemotherapy (NACT) is currently used in patients with locally advanced breast cancer, or in patients with indications for adjuvant chemotherapy and strong breast-conserving needs. It mainly has the following four advantages: first, it can make unresectable tumors resectable; second, it increases the chance of breast conservation; for patients with locally advanced disease and risk of distant metastasis, preoperative systemic therapy is expected to improve the patient’s prognosis. Survival time; tumor shrinkage and imaging changes can be observed, and clinical efficacy can be rapidly evaluated. Therefore, the use of neoadjuvant chemotherapy can signifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G16H70/00G16H70/40G16B20/00G16B25/20G06K9/62
CPCG16H70/00G16H70/40G16B20/00G16B25/20G06F18/23G06F18/24
Inventor 胥顺李坤杨学习
Owner 广州市雄基生物信息技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com